Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX) announced that on October 16, 2024, its Compensation Committee granted an inducement award to a new employee.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chimerix (NASDAQ:CMRX) announced that on October 16, 2024, its Compensation Committee granted an inducement award to a new employee. The award consists of non-statutory stock options to purchase up to 130,000 shares of Chimerix's common stock. This grant was approved as an inducement material to the new employee's employment, in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price equal to Chimerix's closing trading price on the grant date, a 10-year term, and will vest over four years. One-fourth will vest on the one-year anniversary of the hire date, with the remaining three-fourths vesting in equal monthly installments over the following three years. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these options were granted outside of it.
Chimerix is a biopharmaceutical company focused on developing medicines for deadly diseases. Their most advanced clinical-stage program, ONC201, is being developed for H3 K27M-mutant glioma. The company is also conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
Positive
- Granted inducement award to attract new talent
- Advanced clinical-stage development program ONC201 for H3 K27M-mutant glioma
- Conducting Phase 1 dose escalation studies of ONC206
Negative
- None.
Details
News Market Reaction – CMRX
The recorded move for CMRX in the trading session of this news was -0.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.